Thymoquinone / NRF2 Cancer Research Results

TQ, Thymoquinone: Click to Expand ⟱
Features: Anti-oxidant, anti-tumor
Thymoquinone is a bioactive compound found in the seeds of Nigella sativa, commonly known as black seed or black cumin.
Pathways:
-Cell cycle arrest, apoptosis induction, ROS generation in cancer cells
-inhibit the activation of NF-κB, Suppress the PI3K/Akt signaling cascade
-Inhibit angiogenic factors such as VEGF, MMPs
-Inhibit HDACs, UHRF1, and DNMTs

-Note half-life 3-6hrs.
BioAv low oral bioavailability due to its lipophilic nature. Note refridgeration of Black seed oil improves the stability of TQ.
DIY: ~1 part lecithin : 2–3 parts black seed oil : 4–5 parts warm water. (chat ai)
Pathways:
- usually induce ROS production in Cancer cells, and lowers ROS in normal cells
- ROS↑ related: MMP↓(ΔΨm), ER Stress↑, GRP78↑, Cyt‑c↑, Caspases↑, DNA damage↑, cl-PARP↑, HSP↓, Prx,
- May Low AntiOxidant defense in Cancer Cells: NRF2↓">NRF2↓(usually contrary), GSH↓ HO1↓(contrary), GPx↓
- Raises AntiOxidant defense in Normal Cells: ROS↓, NRF2↑">NRF2↑, SOD↑, GSH↑, Catalase↑,
- lowers Inflammation : NF-kB↓, COX2↓, p38↓, Pro-Inflammatory Cytokines : NLRP3↓, IL-1β↓, TNF-α↓, IL-6↓, IL-8↓
- inhibit Growth/Metastases : TumMeta↓, TumCG↓, EMT↓, MMPs↓, MMP2↓, MMP9↓, VEGF↓, FAK↓, NF-κB↓, CXCR4↓, TGF-β↓, ERK↓
- reactivate genes thereby inhibiting cancer cell growth : HDAC↓, DNMTs↓, EZH2↓, P53↑, HSP↓, Sp proteins↓, TET↑
- cause Cell cycle arrest : TumCCA↑, cyclin D1↓, cyclin E↓, CDK2↓, CDK4↓, CDK6↓,
- inhibits Migration/Invasion : TumCMig↓, TumCI↓, TNF-α↓, FAK↓, ERK↓, EMT↓,
- inhibits glycolysis /Warburg Effect and ATP depletion : HIF-1α↓, PKM2↓, cMyc↓, GLUT1↓, LDH↓, LDHA↓, HK2↓, PDKs↓, GRP78↑, GlucoseCon↓
- inhibits angiogenesis↓ : VEGF↓, HIF-1α↓, Notch↓, EGFR↓, Integrins↓,
- Others: PI3K↓, AKT↓, JAK↓, STAT↓, Wnt↓, β-catenin↓, AMPK, α↓, ERK↓, JNK,
- Synergies: chemo-sensitization, chemoProtective, RadioSensitizer, RadioProtective, Others(review target notes), Neuroprotective, Cognitive, Renoprotection, Hepatoprotective, CardioProtective,

- Selectivity: Cancer Cells vs Normal Cells

Rank Pathway / Target Axis Direction Label Primary Effect Notes / Cancer Relevance Ref
1 Reactive oxygen species (ROS) ↑ ROS Driver Upstream cytotoxic trigger Primary studies show TQ rapidly increases ROS; antioxidant/ROS modulation attenuates downstream effects, supporting ROS as an initiating mechanism in multiple cancer contexts (ref)
2 Glutathione (GSH) redox buffering ↓ GSH Driver Redox-collapse amplification Same prostate cancer study reports early GSH depletion alongside ROS rise; together these form a redox “one-two punch” that helps explain selective stress in tumor cells (ref)
3 Mitochondrial integrity (ΔΨm) ↓ ΔΨm Driver Mitochondrial dysfunction (MOMP axis) Primary leukemia/cancer study reports disruption of mitochondrial membrane potential after TQ exposure (mitochondrial events central to TQ-mediated death) (ref)
4 Intrinsic apoptosis (caspase-9 → caspase-3; PARP) ↑ caspases / ↑ apoptosis Driver Execution-phase cell death Same primary paper reports activation of caspases (8/9/3) with mitochondrial involvement—core evidence for apoptosis as the major outcome pathway (ref)
5 NF-κB signaling ↓ NF-κB activity Secondary Reduced pro-survival / inflammatory transcription Colon cancer work: TQ induces cell death and chemosensitizes cells by inhibiting NF-κB signaling (explicit pathway-direction support) (ref)
6 STAT3 signaling ↓ p-STAT3 / ↓ STAT3 activation Secondary Reduced survival/proliferation signaling Gastric cancer study explicitly reports TQ suppresses constitutive STAT3 activation and related signaling readouts (ref)
7 NRF2 antioxidant-response axis (NRF2/HO-1 program) ↑ NRF2 pathway (often as stress-response) Adaptive Cellular antioxidant counter-response In TNBC context, a primary study reports TQ upregulates NRF2 (and evaluates downstream immune/checkpoint consequences), consistent with NRF2 acting as an adaptive response to redox stress (ref)
8 HIF-1α hypoxia signaling ↓ HIF-1α protein / ↓ HIF-1α program Adaptive Loss of hypoxia survival signaling Renal cancer hypoxia paper identifies TQ as suppressing HIF-1α and links this to selective killing under hypoxia (ref)
9 Glycolysis / Warburg output (hypoxia-linked) ↓ glycolysis (↓ HIF-1α–mediated glycolytic genes; ↓ glycolytic metabolism) Phenotypic Metabolic suppression In hypoxic renal cancer, TQ suppresses HIF-1α–mediated glycolysis; in CRC, TQ inhibits glycolytic metabolism alongside tumor growth limitation (ref)  |  (ref)


NRF2, nuclear factor erythroid 2-related factor 2: Click to Expand ⟱
Source: TCGA
Type: Antiapoptotic
Nrf2 is responsible for regulating an extensive panel of antioxidant enzymes involved in the detoxification and elimination of oxidative stress. Thought of as "Master Regulator" of antioxidant response.
-One way to estimate Nrf2 induction is through the expression of NQO1.
NQO1, the most potent inducer:
SFN 0.2 μM,
quercetin (2.5 μM),
curcumin (2.7 μM),
Silymarin (3.6 μM),
tamoxifen (5.9 μM),
genistein (6.2 μM ),
beta-carotene (7.2μM),
lutein (17 μM),
resveratrol (21 μM),
indol-3-carbinol (50 μM),
chlorophyll (250 μM),
alpha-cryptoxanthin (1.8 mM),
and zeaxanthin (2.2 mM)

1. Raising Nrf2 enhances the cell's antioxidant defenses and ↓ROS. This strategy is used to decrease chemo-radio side effects.
2. Downregulating Nrf2 lowers antioxidant defenses and ↑ROS. In cancer cells this leads to DNA damage, and cell death.
3. However there are some cases where increasing Nrf2 paradoxically causes an increase in ROS (cancer cells). Such as cases of Mitochondial overload, signal crosstalk, reductive stress

-In some cases, Nrf2 is overexpressed in cancer cells, which can lead to the activation of genes involved in cell proliferation, angiogenesis, and metastasis. This can contribute to the development of resistance to chemotherapy and targeted therapies.
-Increased Nrf2 expression: Lung, Breast, Colorectal, Prostrate.
Decreased Nrf2 expression: Skine, Liver, Pancreatic.
-Nrf2 is a cytoprotective transcription factor which demonstrated both a negative effect as well as a positive effect on cancer
- "promotes Nrf2 translocation from the cytoplasm to the nucleus," means facilitates the movement of Nrf2 into the nucleus, thereby enhancing the cell's antioxidant and cytoprotective responses. -Major regulator of Nrf2 activity in cells is the cytosolic inhibitor Keap1.

Nrf2 Inhibitors and Activators
Nrf2 Inhibitors: Brusatol, Luteolin, Trigonelline, VitC, Retinoic acid, Chrysin
Nrf2 Activators: SFN, OPZ EGCG, Resveratrol, DATS, CUR, CDDO, Api
- potent Nrf2 inducers from plants include sulforaphane, curcumin, EGCG, resveratrol, caffeic acid phenethyl ester, wasabi, cafestol and kahweol (coffee), cinnamon, ginger, garlic, lycopene, rosemany

Nrf2 plays dual roles in that it can protect normal tissues against oxidative damage and can act as an oncogenic protein in tumor tissue.
– In healthy tissues, NRF2 activation helps protect cells from oxidative damage and maintains cellular homeostasis.
– In many cancers, constitutive activation of NRF2 (often through mutations in NRF2 itself or loss-of-function mutations in KEAP1) leads to an enhanced antioxidant capacity.
– This upregulation can promote tumor cell survival by enabling cancer cells to thrive under oxidative stress, resist chemotherapeutic agents, and sustain metabolic reprogramming.
– Elevated NRF2 levels have been implicated in promoting tumor growth, metastasis, and resistance to therapy in various malignancies.
– High or sustained NRF2 activity is frequently associated with aggressive tumor phenotypes, poorer prognosis, and decreased overall survival in several cancer types.
– While its activation is essential for protecting normal cells from oxidative stress, aberrant or sustained NRF2 activation in tumor cells can lead to enhanced survival, therapeutic resistance, and tumor progression.

NRF2 inhibitors: (to decrease antioxidant defenses and increase cell death from ROS).
-Brusatol: most cited natural inhibitors of Nrf2.
-Luteolin: luteolin can reduce Nrf2 activity in specific cancer models and may enhance cell sensitivity to chemotherapy. However, luteolin is also known as an antioxidant, and its influence on Nrf2 can sometimes be context dependent.
-Apigenin: certain studies to down‑regulate Nrf2 in cancer cells: Dose and context dependent .
-Oridonin:
-Wogonin: although its effects might be cell‑ and dose‑specific.
- Withaferin A

Scientific Papers found: Click to Expand⟱
3409- TQ,    Thymoquinone therapy remediates elevated brain tissue inflammatory mediators induced by chronic administration of food preservatives
- in-vivo, Nor, NA
*MDA↓, *TGF-β↓, *CRP↓, *NF-kB↓, *TNF-α↓, *IL1β↓, *Casp3↓, *GSH↑, *NRF2↑, *IL10↑, *neuroP↑, *ROS↓, *Apoptosis↓, *Inflam↓,
3410- TQ,    Anti-inflammatory effects of thymoquinone and its protective effects against several diseases
- Review, Arthritis, NA
*Inflam↓, *antiOx↑, *COX2↓, *NRF2↑, *HO-1↑, *IL1β↓, *IL6↓, *TNF-α↓, *IFN-γ↓, *PGE2↓, *cardioP↑, *Catalase↑, *SOD↑, *Thiols↑, *neuroP↑, *IL12↓, *MCP1↓, *CXCc↓, *ROS↓,
3404- TQ,    The Neuroprotective Effects of Thymoquinone: A Review
- Review, Var, NA - Review, AD, NA - Review, Park, NA - Review, Stroke, NA
*Inflam↓, AntiCan↑, *TNF-α↓, *IL6↓, *IL1β↓, *NF-kB↓, *iNOS↓, *NRF2↑, *neuroP↑, *MMP↑, *ROS↓, *MDA↓, *GSH↑, *Catalase↑, *SOD↑, *IL12↓, *MCP1↓, *IP-10/CXCL-10↓, *PGE2↓,
3406- TQ,  SeNPs,    A study to determine the effect of nano-selenium and thymoquinone on the Nrf2 gene expression in Alzheimer’s disease
- in-vivo, AD, NA
*NRF2↑, *GSH↑, *MDA↓, *TNF-α↓,
3405- TQ,  doxoR,    Protective effect of thymoquinone against doxorubicin-induced cardiotoxicity and the underlying mechanism
- vitro+vivo, NA, NA
*cardioP↑, *NRF2↑, *HO-1↑, *ROS↓, *NQO1↑, *COX2↓, *NOX4↓, *GPx4↑, *FTH1↑, *p‑mTOR↓, *TGF-β↓,
3402- TQ,    Enhanced Apoptosis in Pancreatic Cancer Cells through Thymoquinone-rich Nigella sativa L. Methanol Extract: Targeting NRF2/HO-1 and TNF-α Pathways
- in-vitro, PC, PANC1 - in-vitro, PC, MIA PaCa-2
tumCV↓, NRF2↑, HO-1↑, TNF-α↓,
3401- TQ,    Molecular mechanisms and signaling pathways of black cumin (Nigella sativa) and its active constituent, thymoquinone: a review
- Review, Var, NA
TumCP↓, *antiOx↑, *ROS↓, NRF2↑, NF-kB↓, TumCCA↑, *GABA↑, P53↑, P21↑, AMPK↑, neuroP↑, cardioP↑, hepatoP↑,
3400- TQ,  Chemo,    Thymoquinone Ameliorates Carfilzomib-Induced Renal Impairment by Modulating Oxidative Stress Markers, Inflammatory/Apoptotic Mediators, and Augmenting Nrf2 in Rats
- in-vitro, Nor, NA
*GSH↑, *SOD↑, *lipid-P↓, *IL1β↓, *IL6↓, *TNF-α↓, *Casp3↓, *Catalase↑, *NRF2↑, *RenoP↑,
3399- TQ,    Anticancer Effects of Thymoquinone through the Antioxidant Activity, Upregulation of Nrf2, and Downregulation of PD-L1 in Triple-Negative Breast Cancer Cells
- in-vitro, BC, MDA-MB-231 - NA, BC, MDA-MB-468
ROS↓, H2O2↓, Catalase↑, SOD↑, GSH↑, NQO1↑, GCLM↑, NRF2↑, PD-L1↓, GSSG↑, GPx1⇅, GPx4↓,
3398- TQ,  5-FU,    Impact of thymoquinone on the Nrf2/HO-1 and MAPK/NF-κB axis in mitigating 5-fluorouracil-induced acute kidney injury in vivo
- in-vivo, Nor, NA
*RenoP↑, *TAC↑, *ROS↓, *lipid-P↓, *p38↓, *MAPK↓, *NF-kB↓, *NRF2↑, *HO-1↑, *MDA↓, *GPx↑, *GSR↑, *Catalase↑, *BUN↓, *LDH↓, *IL1β↓,
2135- TQ,    Thymoquinone induces heme oxygenase-1 expression in HaCaT cells via Nrf2/ARE activation: Akt and AMPKα as upstream targets
- in-vitro, Nor, HaCaT
*HO-1↑, *NRF2↑, *e-ERK↑, *e-Akt↑, *AMPKα↑, *ROS⇅, *eff↓, *tumCV∅,
4538- TQ,    NRF2_and_the_Downregulation_of_PD-L1_in_MDA-MB-231_Triple-Negative_Breast_Cancer_Cells">Thymoquinone Anticancer Effects Through the Upregulation of NRF2 and the Downregulation of PD‐L1 in MDA‐MB‐231 Triple‐Negative Breast Cancer Cells
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MDA-MB-468
antiOx↑, H2O2↓, Catalase↑, SOD↑, GSH↑, PRNP↑, NQO1↑, GCLM↑, NRF2↑, PD-L1↓, chemoPv↑, ROS↓,
5024- TQ,    Thymoquinone: A Tie-Breaker in SARS-CoV2-Infected Cancer Patients?
- Review, Covid, NA
*NRF2↑, *NF-kB↓, *Inflam↓, *ROS↓, *HO-1↑, antiOx↑, GSH↑, GSTs↑, GSR↑, SOD1↑, Catalase↑, GPx↑, p62↓, Beclin-1↑, Sepsis↓, cardioP↑, hepatoP↑, neuroP↑,
3559- TQ,    Molecular signaling pathway targeted therapeutic potential of thymoquinone in Alzheimer’s disease
- Review, AD, NA - Review, Var, NA
*antiOx↑, *Inflam↓, *AChE↓, AntiCan↑, *cardioP↑, *RenoP↑, *neuroP↑, *hepatoP↑, TumCG↓, Apoptosis↑, PI3K↓, Akt↑, TumCCA↑, angioG↓, *NF-kB↓, *TLR2↓, *TLR4↓, *MyD88↓, *TRIF↓, *IRF3↓, *IL1β↓, *IL6↓, *IL12↓, *NRF2↑, *COX2↓, *VEGF↓, *MMP9↓, *cMyc↓, *cycD1/CCND1↓, *TumCP↓, *TumCI↓, *MDA↓, *TGF-β↓, *CRP↓, *Casp3↓, *GSH↑, *IL10↑, *iNOS↑, *lipid-P↓, *SOD↑, *H2O2↓, *ROS↓, *LDH↓, *Catalase↑, *GPx↑, *AChE↓, *cognitive↑, *MAPK↑, *JNK↑, *BAX↓, *memory↑, *Aβ↓, *MMP↑,
2134- TQ,    Modulation of Nrf2/HO1 Pathway by Thymoquinone to Exert Protection Against Diazinon-induced Myocardial Infarction in Rats
- in-vivo, Nor, NA
*ALAT↓, *AST↓, *MDA↓, *ROS↓, *GSSG↓, *GSH↑, *VitE↑, *VitC↑, *NRF2↑, *HO-1↑, *NQO1↑, *SOD↑, *cardioP↑, *GSH/GSSG↑, *GPx↑,
1052- TQ,    Thymoquinone Anticancer Effects Through the Upregulation of NRF2 and the Downregulation of PD-L1 in MDA-MB-231 Triple-Negative Breast Cancer Cells
- in-vitro, BC, MDA-MB-231
NRF2↑, PD-L1↓, Apoptosis↑,
2126- TQ,    Biological and therapeutic activities of thymoquinone: Focus on the Nrf2 signaling pathway
- Review, Nor, NA
*antiOx↑, *Bacteria↓, *RenoP↑, *hepatoP↑, *neuroP↑, *Inflam↓, *Keap1↓, *NRF2↑, *other↝,
2130- TQ,    Thymoquinone Attenuates Brain Injury via an Anti-oxidative Pathway in a Status Epilepticus Rat Model
- in-vivo, Nor, NA
*eff↑, *memory↑, *NRF2↑, *HO-1↑, *SOD↑, *ROS↓,
2131- TQ,    Therapeutic impact of thymoquninone to alleviate ischemic brain injury via Nrf2/HO-1 pathway
- in-vitro, Stroke, NA - in-vivo, Nor, NA
*eff↑, *OS↑, *Inflam↓, *ROS↓, *NRF2↑, *HO-1↑,
2133- TQ,  CUR,  Cisplatin,    Thymoquinone and curcumin combination protects cisplatin-induced kidney injury, nephrotoxicity by attenuating NFκB, KIM-1 and ameliorating Nrf2/HO-1 signalling
- in-vitro, Nor, HEK293 - in-vivo, NA, NA
*creat↓, *TNF-α↓, *IL6↓, *MRP↓, *GFR↑, *mt-ATPase↑, *p‑Akt↑, *NRF2↑, *HO-1↑, *Casp3↓, *NF-kB↓, *RenoP↑,
2106- TQ,    Cancer: Thymoquinone antioxidant/pro-oxidant effect as potential anticancer remedy
- Review, Var, NA
Apoptosis↑, TumCCA↑, ROS↑, *Catalase↑, *SOD↑, *GR↑, *GSTA1↓, *GPx↑, *H2O2↓, *ROS↓, *lipid-P↓, *HO-1↑, p‑Akt↓, AMPKα↑, NK cell↑, selectivity↑, Dose↝, eff↑, GSH↓, eff↓, P53↑, p‑STAT3↓, PI3K↑, MAPK↑, GSK‐3β↑, ChemoSen↑, RadioS↑, BioAv↓, NRF2↑,

Showing Research Papers: 1 to 21 of 21

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 21

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 2,   Catalase↑, 3,   GCLM↑, 2,   GPx↑, 1,   GPx1⇅, 1,   GPx4↓, 1,   GSH↓, 1,   GSH↑, 3,   GSR↑, 1,   GSSG↑, 1,   GSTs↑, 1,   H2O2↓, 2,   HO-1↑, 1,   NQO1↑, 2,   NRF2↑, 6,   ROS↓, 2,   ROS↑, 1,   SOD↑, 2,   SOD1↑, 1,  

Core Metabolism/Glycolysis ⓘ

AMPK↑, 1,  

Cell Death ⓘ

Akt↑, 1,   p‑Akt↓, 1,   Apoptosis↑, 3,   MAPK↑, 1,  

Kinase & Signal Transduction ⓘ

AMPKα↑, 1,  

Transcription & Epigenetics ⓘ

tumCV↓, 1,  

Autophagy & Lysosomes ⓘ

Beclin-1↑, 1,   p62↓, 1,  

DNA Damage & Repair ⓘ

P53↑, 2,  

Cell Cycle & Senescence ⓘ

P21↑, 1,   TumCCA↑, 3,  

Proliferation, Differentiation & Cell State ⓘ

GSK‐3β↑, 1,   PI3K↓, 1,   PI3K↑, 1,   p‑STAT3↓, 1,   TumCG↓, 1,  

Migration ⓘ

PRNP↑, 1,   TumCP↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,  

Immune & Inflammatory Signaling ⓘ

NF-kB↓, 1,   NK cell↑, 1,   PD-L1↓, 3,   TNF-α↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,   ChemoSen↑, 1,   Dose↝, 1,   eff↓, 1,   eff↑, 1,   RadioS↑, 1,   selectivity↑, 1,  

Clinical Biomarkers ⓘ

PD-L1↓, 3,  

Functional Outcomes ⓘ

AntiCan↑, 2,   cardioP↑, 2,   chemoPv↑, 1,   hepatoP↑, 2,   neuroP↑, 2,  

Infection & Microbiome ⓘ

Sepsis↓, 1,  
Total Targets: 57

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 4,   Catalase↑, 6,   GPx↑, 4,   GPx4↑, 1,   GSH↑, 6,   GSH/GSSG↑, 1,   GSR↑, 1,   GSSG↓, 1,   GSTA1↓, 1,   H2O2↓, 2,   HO-1↑, 10,   Keap1↓, 1,   lipid-P↓, 4,   MDA↓, 6,   NOX4↓, 1,   NQO1↑, 2,   NRF2↑, 15,   ROS↓, 12,   ROS⇅, 1,   SOD↑, 7,   TAC↑, 1,   Thiols↑, 1,   VitC↑, 1,   VitE↑, 1,  

Metal & Cofactor Biology ⓘ

FTH1↑, 1,  

Mitochondria & Bioenergetics ⓘ

MMP↑, 2,  

Core Metabolism/Glycolysis ⓘ

ALAT↓, 1,   BUN↓, 1,   cMyc↓, 1,   LDH↓, 2,  

Cell Death ⓘ

p‑Akt↑, 1,   e-Akt↑, 1,   Apoptosis↓, 1,   BAX↓, 1,   Casp3↓, 4,   iNOS↓, 1,   iNOS↑, 1,   JNK↑, 1,   MAPK↓, 1,   MAPK↑, 1,   p38↓, 1,  

Kinase & Signal Transduction ⓘ

AMPKα↑, 1,  

Transcription & Epigenetics ⓘ

other↝, 1,   tumCV∅, 1,  

Cell Cycle & Senescence ⓘ

cycD1/CCND1↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

e-ERK↑, 1,   p‑mTOR↓, 1,  

Migration ⓘ

mt-ATPase↑, 1,   MMP9↓, 1,   TGF-β↓, 3,   TumCI↓, 1,   TumCP↓, 1,  

Angiogenesis & Vasculature ⓘ

VEGF↓, 1,  

Barriers & Transport ⓘ

MRP↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 3,   CRP↓, 2,   CXCc↓, 1,   IFN-γ↓, 1,   IL10↑, 2,   IL12↓, 3,   IL1β↓, 6,   IL6↓, 5,   Inflam↓, 7,   IP-10/CXCL-10↓, 1,   MCP1↓, 2,   MyD88↓, 1,   NF-kB↓, 6,   PGE2↓, 2,   TLR2↓, 1,   TLR4↓, 1,   TNF-α↓, 6,   TRIF↓, 1,  

Synaptic & Neurotransmission ⓘ

AChE↓, 2,   GABA↑, 1,  

Protein Aggregation ⓘ

Aβ↓, 1,  

Hormonal & Nuclear Receptors ⓘ

GR↑, 1,  

Drug Metabolism & Resistance ⓘ

eff↓, 1,   eff↑, 2,  

Clinical Biomarkers ⓘ

ALAT↓, 1,   AST↓, 1,   creat↓, 1,   CRP↓, 2,   IL6↓, 5,   LDH↓, 2,  

Functional Outcomes ⓘ

cardioP↑, 4,   cognitive↑, 1,   GFR↑, 1,   hepatoP↑, 2,   memory↑, 2,   neuroP↑, 5,   OS↑, 1,   RenoP↑, 5,  

Infection & Microbiome ⓘ

Bacteria↓, 1,   IRF3↓, 1,  
Total Targets: 94

Scientific Paper Hit Count for: NRF2, nuclear factor erythroid 2-related factor 2
21 Thymoquinone
1 Selenium NanoParticles
1 doxorubicin
1 Chemotherapy
1 5-fluorouracil
1 Curcumin
1 Cisplatin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:162  Target#:226  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page